RxDoctor Payments Data

Gustavo Polanco Hernandez, PA

Physician Assistant · Bronx, NYNPI 1013558188

Payments from drug & device makers

$1,669in general payments, 2019–2025

Across 42 payments — averaging $39.73 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Viiv Healthcare Company$506
  • Lilly USA, LLC$254
  • GSK$175
  • Globus Medical$130
  • Bayer$125
  • AbbVie$121
  • plus $359 from 12 others

What the payments were for

  • Food & beverage$1,669100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,669 in reported general payments places this provider in the 80th percentile of 11,358 physician assistant providers in New York.

See all physician assistant providers in New York

Medicare billing

Part B allowed, 2024
$21,502
Medicare patients
81
Services billed
293

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
JardianceEmpagliflozin79$82,020
TrulicityDulaglutide55$66,566
OzempicSemaglutide29$33,815
FarxigaDapagliflozin Propanediol38$33,404
JanuviaSitagliptin Phosphate25$25,092
LinzessLinaclotide30$23,626
XareltoRivaroxaban15$16,219
JanumetSitagliptin Phos/Metformin Hcl11$14,286
Diclofenac Sodium ErDiclofenac Sodium110$8,491
Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog20$5,988
Doxepin Hcl52$5,451
Diclofenac Sodium22$5,385
Albuterol Sulfate HfaAlbuterol Sulfate115$5,205
Metformin Hcl128$3,604
Atorvastatin Calcium238$2,778

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Lilly USA, LLCTrulicity$254$66,56655 claims
Novo NordiskOzempic$15$33,81529 claims
AstraZenecaFarxiga$96$33,40438 claims
AbbVieLinzess$121$23,62630 claims
Johnson & JohnsonXarelto$24$16,21915 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 11,358 physician assistant providers in New York.

Other physician assistant in Bronx

See the full list for New York

Where these figures come from

Is this you, or does something look wrong? →